Lexaria BioScience begins trading on the Nasdaq Exchange in the United States

Lexaria BioScience (NASDAQ: LEXX- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive to bring news the company is now trading on the Nasdaq capital markets. That includes an offering with gross proceeds of 9.6 million.

Bunka telling Proactive what has gotten the company to this point and why the move was made, He also talked about what he feels will be a big 2021 for Lexaria.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE
InnoCan Pharma announces successful completion of ...
Lexaria Bioscience prices $9.6M public offering as...

By accepting you will be accessing a service provided by a third-party external to https://www.mjinvest.com/